Key points are not available for this paper at this time.
Although several facets of this manufacturing process still need to be improved, these data may yet provide a useful platform for the production of hESC-derived cardiac progenitor cells under safe and cost-effective GMP conditions.
Menasché et al. (Fri,) studied this question.